May 30, 2025 10:15 AM EDT

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

ENDPOINTS

Plus, news about Diakonos Oncology and Coherus:

Roche’s longer-term data for multiple sclerosis drug: The Swiss drugmaker’s BTK inhibitor fenebrutinib

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit’s disappointing survival readout raises stakes for full data

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation